Dr. Alan Tan, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 109
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TN license 70201 · IN license 01071270A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Vanderbilt University Medical Center Nashville, TN
- Vanderbilt Wilson County Hospital Lebanon, TN
Medical groups
- Vanderbilt Health Clinicians, LLC (129 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 109
- Services billed
- 290
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 230 | 108 |
| New patient office or other outpatient visit, 60-74 minutes | 32 | 32 |
| Telephone medical discussion with physician, 21-30 minutes | 23 | 20 |
| Established patient office or other outpatient visit, 30-39 minutes | 22 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Orgovyx (relugolix) | 84 |
| Nubeqa (darolutamide) | 52 |
| Prednisone Other prescribers in Nashville, TN | 42 |
| Abiraterone Acetate | 32 |
| Xtandi (enzalutamide) | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 84 payments worth $125,610 in total to this clinician.
| Aveo Pharmaceuticals, Inc. | $42,477 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $35,889 |
| Exelixis Inc. | $22,807 |
| Pfizer Inc. | $9,133 |
| Merck Sharp & Dohme LLC | $4,478 |
| Roche Diagnostics International LTD | $4,242 |
| Astellas Pharma US Inc | $3,870 |
| Janssen Biotech, Inc. | $2,348 |
| Compensation for services other than consulting (speaking, faculty) | $74,615 |
|---|---|
| Consulting Fee | $23,160 |
| Speaking at a medical education program | $20,625 |
| Travel and Lodging | $5,180 |
| Food and Beverage | $1,987 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) OPDIVO · Oncology | $11,385 |
| Aveo Pharmaceuticals, Inc. Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology | $7,245 |
| Aveo Pharmaceuticals, Inc. Sep 23, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $7,245 |
| Aveo Pharmaceuticals, Inc. Oct 9, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $7,245 |
| E.r. Squibb & Sons, L.l.c. May 27, 2025 | Consulting Fee | $6,760 |
| Exelixis Inc. Sep 24, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $4,455 |
| Merck Sharp & Dohme LLC Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $4,270 |
| E.r. Squibb & Sons, L.l.c. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) OPDIVO · Oncology | $3,623 |
| E.r. Squibb & Sons, L.l.c. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) OPDIVO · Oncology | $3,623 |
| Pfizer Inc. Jul 30, 2025 | Consulting Fee PADCEV · ONCOLOGY | $3,000 |
All 65 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. Dec 23, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $2,013 |
| E.r. Squibb & Sons, L.l.c. Dec 19, 2025 | Consulting Fee | $520 |
| Exelixis Inc. Dec 9, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,980 |
| Roche Diagnostics International LTD Dec 4, 2025 | Consulting Fee | $1,061 |
| Merck Sharp & Dohme LLC Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $4,270 |
| Merck Sharp & Dohme LLC Dec 2, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Paducah, KY | $150 |
| Pfizer Inc. Nov 24, 2025 | Consulting Fee PADCEV · ONCOLOGY | $3,000 |
| Exelixis Inc. Nov 19, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,980 |
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
| Astellas Pharma US Inc Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) Padcev · Oncology | $2,580 |
| Exelixis Inc. Oct 14, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,980 |
| Aveo Pharmaceuticals, Inc. Oct 9, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $7,245 |
| Aveo Pharmaceuticals, Inc. Oct 9, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to Chicago, IL Company’s descriptionGround Transportation OOP | $156 |
| Aveo Pharmaceuticals, Inc. Oct 9, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to Chicago, IL Company’s descriptionAirfare Other OOP | $8.00 |
| Aveo Pharmaceuticals, Inc. Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $2,013 |
| Exelixis Inc. Oct 1, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,980 |
| Aveo Pharmaceuticals, Inc. Sep 27, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to The Woodlands, TX · in-kind Company’s descriptionAirfare | $364 |
| Aveo Pharmaceuticals, Inc. Sep 27, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to The Woodlands, TX · in-kind Company’s descriptionHotel | $309 |
| Exelixis Inc. Sep 25, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $185 |
| Exelixis Inc. Sep 25, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $185 |
| Exelixis Inc. Sep 24, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $4,455 |
| Aveo Pharmaceuticals, Inc. Sep 23, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $7,245 |
| Exelixis Inc. Sep 20, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $336 |
| Exelixis Inc. Sep 20, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL | $159 |
| Exelixis Inc. Sep 20, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $70.00 |
| Exelixis Inc. Sep 20, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL | $8.00 |
| Janssen Biotech, Inc. Sep 19, 2025 | Consulting Fee ERLEADA · Oncology | $1,010 |
| Aveo Pharmaceuticals, Inc. Sep 13, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to Chicago, IL · in-kind Company’s descriptionAirfare | $455 |
| Exelixis Inc. Aug 29, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $478 |
| Exelixis Inc. Aug 29, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $49.44 |
| Exelixis Inc. Aug 29, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $49.44 |
| Exelixis Inc. Aug 19, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,980 |
| Pfizer Inc. Jul 30, 2025 | Consulting Fee PADCEV · ONCOLOGY | $3,000 |
| Aveo Pharmaceuticals, Inc. Jul 30, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $2,013 |
| Aveo Pharmaceuticals, Inc. Jul 30, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $2,013 |
| Exelixis Inc. Jul 29, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,980 |
| Roche Diagnostics International LTD Jul 27, 2025 | Consulting Fee | $530 |
| Aveo Pharmaceuticals, Inc. Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $2,013 |
| Aveo Pharmaceuticals, Inc. Jul 10, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology | $2,013 |
| Astellas Pharma US Inc Jul 3, 2025 | Compensation for services other than consulting (speaking, faculty) Padcev · Oncology | $1,290 |
| Roche Diagnostics International LTD Jul 2, 2025 | Consulting Fee | $530 |
| Exelixis Inc. Jul 1, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,980 |
| Exelixis Inc. Jun 26, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $330 |
| Aveo Pharmaceuticals, Inc. Jun 18, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to Orlando, FL | $74.79 |
| Aveo Pharmaceuticals, Inc. Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology | $7,245 |
| E.r. Squibb & Sons, L.l.c. May 27, 2025 | Consulting Fee | $6,760 |
| Aveo Pharmaceuticals, Inc. May 17, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to Orlando, FL · in-kind | $453 |
| Aveo Pharmaceuticals, Inc. May 17, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to Orlando, FL · in-kind | $303 |
| Aveo Pharmaceuticals, Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology | $2,013 |
| Aveo Pharmaceuticals, Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology | $2,013 |
| E.r. Squibb & Sons, L.l.c. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) OPDIVO · Oncology | $3,623 |
| E.r. Squibb & Sons, L.l.c. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) OPDIVO · Oncology | $3,623 |
| Aveo Pharmaceuticals, Inc. Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology | $2,013 |
| Roche Diagnostics International LTD Apr 28, 2025 | Consulting Fee | $1,061 |
| E.r. Squibb & Sons, L.l.c. Apr 28, 2025 | Consulting Fee | $518 |
| Pfizer Inc. Apr 23, 2025 | Consulting Fee PADCEV · ONCOLOGY | $3,000 |
| E.r. Squibb & Sons, L.l.c. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) OPDIVO · Oncology | $11,385 |
| Janssen Biotech, Inc. Mar 28, 2025 | Consulting Fee ERLEADA · Oncology | $1,110 |
| Roche Diagnostics International LTD Mar 28, 2025 | Consulting Fee | $1,061 |
| E.r. Squibb & Sons, L.l.c. Mar 28, 2025 | Travel and Lodging OPDIVO · Oncology · travel to Fort Walton Beach, FL | $626 |
| E.r. Squibb & Sons, L.l.c. Mar 13, 2025 | Travel and Lodging OPDIVO · Oncology · travel to Fort Walton Beach, FL | $761 |
| Exelixis Inc. Feb 11, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,980 |
| E.r. Squibb & Sons, L.l.c. Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) OPDIVO · Oncology | $2,664 |
| E.r. Squibb & Sons, L.l.c. Jan 23, 2025 | Compensation for services other than consulting (speaking, faculty) OPDIVO · Oncology | $2,664 |
| E.r. Squibb & Sons, L.l.c. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) OPDIVO · Oncology | $2,664 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $2,689,577 in research payments for these studies, mostly to the institutions running them.
- A Phase 1 , Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan MK-6482 in Participants With Advanced Clear Cell Renal Cell Carcinoma ccRCC
Merck Sharp & Dohme LLC - An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembro…
Merck Sharp & Dohme LLC - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Aveo Pharmaceuticals, Inc. · Completed · NCT04987203
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.